Categories: Wire Stories

Asia Pacific Pharmaceutical Analytical Testing Outsourcing Market to Reach $302.3 Billion 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Pharmaceutical Analytical Testing Outsourcing Market 2021-2031 by Service Type, Product Type, End User, Organization Size, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.

Asia Pacific pharmaceutical analytical testing outsourcing market will grow by 10.2% annually with a total addressable market cap of $30,233.3 million over 2022-2031, driven by the increasing pipelines for drug candidates, rising demand for additional analytical details on drugs as well as process development by regulatory agencies, entry of new contract organizations, and the lack of in-house equipment along with the rising adoption of outsourcing activities.

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Five Forces

Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • Bioanalytical Testing
  • Clinical Testing
  • Non-clinical Testing
  • Method Development and Validation
  • Extractable & Leachable
  • Impurity Method
  • Technical Consulting
  • Other Methods
  • Stability Testing
  • Drug Substances Testing
  • Accelerated Stability Testing
  • Photostability Testing
  • Other Stability Testings
  • Other Services

Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • Raw Materials & Additives
  • Active Pharmaceutical Ingredients (APIs)
  • Finished Products

By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • Pharmaceutical & Biopharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Other End Users

By Organization Size, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • SMEs
  • Large Enterprises

Geographically, the following national/local markets are fully investigated:

  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

Key Topics Covered:

1 Introduction

2 Market Overview and Dynamics

3 Segmentation of Asia Pacific Market by Service Type

4 Segmentation of Asia Pacific Market by Product Type

5 Segmentation of Asia Pacific Market by End User

6 Segmentation of Asia Pacific Market by Organization Size

7 Asia-Pacific Market 2021-2031 by Country

8 Competitive Landscape

Companies Mentioned

  • Boston Analytical, Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • Exova Group PLC
  • Intertek Pharmaceutical Services
  • Laboratory Testing Inc.
  • Pace Analytical Services LLC
  • Pharmaceutical Product Development, LLC
  • SGS SA
  • Steris PLC
  • Tentamus
  • Toxikon Inc.
  • West Pharmaceutical Services Inc.
  • WuXi AppTec, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/2vyuk5

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Alex

Recent Posts

GAMCO Board Declares Special Dividend of $0.20 per share and Regular Quarterly Dividend of $0.04 per share

GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GAMCO Investors, Inc. (“GAMI”) (OTCQX: GAMI) announced…

6 mins ago

Coeur to Participate in Upcoming Canaccord Global Metals & Mining Conference

CHICAGO--(BUSINESS WIRE)--Coeur Mining, Inc.’s (“Coeur” or the “Company”) (NYSE: CDE) Senior Vice President and Chief…

7 mins ago

LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis

Enstilar® (LEO 90100) showed superiority over Daivobet® ointment in primary and both secondary endpoints in…

2 hours ago

Apromore Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining Platforms Report

Recognized a Leader for Second Consecutive Year Based on Completeness Of Vision and Ability To…

3 hours ago

Luxshare Precision Reinforces Commitment to Ethical Practices

HONG KONG SAR - Media OutReach Newswire - 7 May 2024 - Luxshare Precision, a…

4 hours ago

ServiceNow and Fujitsu announce strategic commitment to launch innovative cross-industry solutions

ServiceNow’s AI platform for digital business, combined with Fujitsu industry expertise, will maximize value for…

4 hours ago